Ceretas (ASX:CTS) is one of the newest names on the ASX boards, a University of Queensland spin-out that listed with an ambitious pitch: a portable, non-invasive ultrasound platform designed to treat Alzheimer's disease and other neurodegenerative conditions.

Ceretas debuted on the ASX under the ticker CTS, raising approximately A$8 million at 25 cents per share through the issue of 32 million shares, for an implied Market Capitalisation of around A$18 million at the offer price.

The technology is the real point of difference. Ceretas has licensed intellectual property from the Queensland Brain Institute, developed by Professor Jurgen Gotz, that uses low-intensity therapeutic ultrasound directed at the brain. The approach aims to enhance communication between neurons and activate the brain's natural mechanisms for clearing toxic amyloid and tau proteins, the hallmark pathologies of Alzheimer's, and, importantly, does so without the injected microbubbles used in earlier ultrasound research. That points toward a portable, potentially more accessible treatment platform if the clinical work bears out. The near-term corporate agenda centres on advancing Clinical Trials and engaging regulators such as the TGA and FDA.

What could drive the shares from here?

The catalysts from here are clinical and regulatory. Progress into and through human clinical trials, positive early efficacy or safety signals, and constructive engagement with the TGA and FDA would each be meaningful for a company of this size. Partnerships with research institutions, larger MedTech or pharmaceutical players, or grant funding could validate the platform and extend the runway. Given the tiny float and register, positive newsflow could move the shares sharply. Broader investor appetite for Alzheimer's-focused therapeutics, an area of intense global interest, also shapes sentiment toward the name.

Risks investors should watch

The risks are substantial and typical of early-stage medtech. Alzheimer's has a long history of clinical failure, and a novel ultrasound mechanism, however promising, is unproven in the clinic at scale. The A$8 million raised is modest relative to the cost of running clinical programs, so dilution risk through future capital raisings is high. As a freshly listed micro-cap, the stock is Illiquid and volatile, and its debut premium could unwind as easily as it built. Regulatory pathways for a novel therapeutic device are uncertain and can be slow. Reliance on licensed university IP and key scientific personnel adds concentration risk. This is a speculative holding by any reasonable standard.

Investor takeaway

Ceretas offers a differentiated, genuinely interesting idea, portable therapeutic ultrasound aimed at clearing the proteins implicated in Alzheimer's, backed by respected institutional science and a successful, in-demand float. The bull case is that early clinical validation of a non-invasive, accessible platform in a huge unmet need could be transformative. The bear case is sobering: Alzheimer's is a graveyard for treatments, the company is pre-revenue with a small cash balance, and a recently listed micro-cap trading above issue price carries real downside if enthusiasm fades or trials disappoint. Key milestones to watch are clinical-trial progress, regulatory engagement and the timing and size of the next capital raise.